[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
From the Food and Drug Administration
January 6, 1999

New Requirement for Patient Labeling for Selected Prescription Drug Products

Author Affiliations

Not Available

Not Available

JAMA. 1999;281(1):27. doi:10.1001/jama.281.1.27-JFD80012-2-1

The FDA has issued a final rule establishing requirements for the distribution of patient labeling for selected prescription drug and biological products used primarily on an outpatient basis. The agency is requiring the distribution of patient labeling, called Medication Guides, for a small number of products that the agency believes pose a serious and significant public health concern necessitating this distribution. The agency will require Medication Guides if one or more of the following circumstances exists: (1) the product is one for which labeling could help prevent serious adverse effects or (2) the product has serious risks that could affect patients' decision to use, or to continue to use, the product or (3) the product is important to health and patient adherence to directions for use is crucial to the drug's effectiveness.

First Page Preview View Large
First page PDF preview
First page PDF preview